Investment firm Bain Capital has bought Japanese company Mitsubishi Tanabe Pharma Corporation in a $3.3bn deal. Tanabe Pharma had revenue of approximately $2.89bn during the fiscal year ending 31 March 2024, an 18.3% decrease from the previous fiscal year. Its R&D spending of around $415.5m was more than that of all other Mitsubishi Chemical Group divisions combined. The purchase gives Bain access to a variety of products and a drug pipeline across various key therapeutic areas.
The US relies on China for key medicines. They won't be spared from tariffs
US tariffs on all Chinese imports are likely to jeopardize a significant portion of pharmaceuticals that Americans use daily. Chinese imports account for a large
